Calcium gluconate-Vial - instructions for use, dose, side effects, contraindications

The preparation of calcium replenishes the deficiency of calcium ions necessary for the process of nerve impulse transmission, reduction of skeletal and smooth muscles, myocardial activity, bone formation, and clotting of blood.

With intravenous injection stimulates the sympathetic division of the autonomic nervous system, enhances the secretion of epinephrine by the adrenal glands, and has a moderate diuretic effect.

Pharmacokinetics:

After parenteral administration, the drug with blood flow is evenly distributed in all tissues and organs. In plasma about 45% is in complex with proteins. Passes through the placental barrier, enters the breast milk. It is excreted from the body mainly by the kidneys.

Indications:

Diseases accompanied by: hypocalcemia, increased permeability of cell membranes (including blood vessels), impaired conduction of nerve impulses in muscle tissue.

Hypoparathyroidism (latent tetany, osteoporosis), a violation of vitamin exchange D: rickets (spasmophilia, osteomalacia), hyperphosphatemia in patients with chronic renal insufficiency.

Increased need for calcium (pregnancy, lactation, a period of increased body growth), insufficient calcium in the diet, a violation of its metabolism (in the postmenopausal period).

Enhanced excretion of calcium (prolonged bed rest, chronic diarrhea, secondary hypocalcemia, long-term use of diuretics and antiepileptic drugs, glucocorticosteroids).

Bleeding of various etiologies; allergic diseases (serum sickness, urticaria, febrile syndrome, pruritus, pruritic dermatoses, response to drug administration and food intake, angioneurotic edema); bronchial asthma, dystrophic alimentary swelling, pulmonary tuberculosis, rickets, osteomalacia, lead colic; eclampsia.

Parenchymal hepatitis, toxic liver damage, nephritis, hyperkalemic form of paroxysmal myoplegia.

Contraindications:

Hypersensitivity, hypercalcemia (Ca 2+ concentration should not exceed 12 mg% or 6 mEq / L), expressed hypercalciuria, nephrourolythiasis (calcium), sarcoidosis, simultaneous reception of cardiac glycosides (risk of arrhythmias).

Carefully:

Dehydration, electrolyte disturbances (risk of hypercalcemia), diarrhea, calcium nefrourolitiaz (in history), hypercalciuria slight, moderate chronic renal insufficiency, chronic circulatory insufficiency, widespread atherosclerosis, hypercoagulation, children's age (for intramuscular injection - the risk of necrosis).

Dosing and Administration:

Intramuscularly, intravenously slowly (within 2-3 minutes) or drip, adult - 5-10 ml of 10% solution daily, every other day or through 2 days (depending on the nature of the disease and the patient's condition). Children - intravenously slowly (within 2-3 minutes) or drip, depending on the age, from 1 to 5 ml of 10% solution every 2-3 days. The solution before the introduction is warmed to body temperature. The syringe for the administration of calcium gluconate should not contain ethanol residues (in order to avoid the precipitation of calcium gluconate). Children intramuscularly administered the drug is not recommended because of the possible development of necrosis.

Side effects:

With intramuscular and intravenous administration, nausea, vomiting, diarrhea, and bradycardia can occur. With intravenous administration, burning in the oral cavity, a sensation of fever, with a rapid intravenous injection - a decrease in blood pressure, arrhythmia, fainting, cardiac arrest can be observed. With intramuscular injection, necrosis can occur at the site of administration.

Overdose:

Symptoms: hypercalcemia.

Treatment: calcitonin, intravenously at the rate of 5-10 IU / kg bw / day (the drug is diluted in 500 ml of 0.9 % solution of sodium chloride, injected drip for 6 hours).

Interaction:

Pharmaceutically compatible with ethanol, carbonates, salitsilata- E, sulfates (forms insoluble or poorly soluble calcium salt). Forms insoluble complexes with antibiotics of the tetracycline series (reduces the antibacterial effect).

Reduces the effect of blockers of "slow" calcium channels (intravenous calcium gluconate before and after verapamil reduces its hypotensive effect).

With simultaneous application with quinidine, it is possible to slow intraventricular conduction and increase the toxicity of quinidine.

During the treatment with cardiac glycosides, parenteral calcium gluconate is not recommended (cardiotoxic effect of glycosides may be increased).

When combined with the thiazide diuretics may enhance hypercalcemia calcitonin reduce hypercalcemia effect, reduces the bioavailability of phenytoin.

Special instructions:

Patients with small hypercalciuria, decreased glomerular filtration rate, or with a history of nefrourolitiazom appointment should be made with caution and under the control of calcium in the urine.Drinking plenty is recommended to reduce the risk of nephrourolythiasis.

Form release / dosage:Solution for intravenous and intramuscular injection 100 mg / ml.

Packaging:Solution for intravenous and intramuscular injection 100 mg / ml in neutral colorless glass ampoules of 10 ml.

10 ampoules per contour cell package. One contour pack with the instruction for use is enclosed in a cardboard box.

Storage conditions:In the dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.

Shelf life:

3 years. Do not use after the expiry date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:LSR-004482/07

Date of registration:06.12.2007

The owner of the registration certificate:VIAL, LLC VIAL, LLC Russia

Manufacturer: & nbsp

NORTH CHINA PHARMACEUTICAL CORPORATION China

Information update date: & nbsp10.09.2015

Illustrated instructions

Instructions

Calcium gluconate-Vial (Calcium gluconate-Vial)